Guerbet: Revenue at 30 September 2019
25 October 2019 - 2:47AM
Guerbet: Revenue at 30 September 2019
Revenue at 30 September 2019
Solid growth during the 3rd quarter, in line with
the 2019 objectives
- Revenue of €603.5 million for the first 9 months
- Up 3.8% at current exchange rates and 2.2% at constant exchange
rates
- Annual objectives confirmed
Villepinte, 24 October 2019 -
Guerbet (FR0000032526 GBT), a global specialist in
contrast agents and solutions for medical imaging, has announced
its revenue for the first nine months of its 2019 financial
year.
As of September 30th, reported revenues were
€603.5 million, increasing by 3.8% compared to September 30th
2018, including a favourable forex impact of €9.2 million. At
constant exchange rates revenues of €594.3 million are up
2.2%. Nine months sales have been impacted by the decrease of
subcontracting activities inherited from the CMDS. Without this
impact, at constant exchange rate, revenues have grown 4.0% during
the first nine months of the 2019 financial year.
Consolidated Group revenue
(IFRS)
In
millions of euros,at 30 September 2019 |
Change
(%) |
2019at current exchange
rates |
Change
(%) |
2019at constant exchange
rates* |
Reported 2018 |
Sales in Europe |
+0.4% |
255.0 |
+0.9% |
256.4 |
254.1 |
Sales in Other Markets |
+6.5% |
348.5 |
+3.3% |
338.1 |
327.3 |
Total |
+3.8% |
603.5 |
+2.2% |
594.3 |
581.4 |
All regions are showing growth. In Europe sales
increase was driven by Optiray® and Dotarem®. In Other Markets,
sales continued to grow in the Americas and in Asia with the switch
to direct distribution in Japan.
The analysis of the activity over the first nine
months of the financial year shows:
- Diagnostic Imaging sales growing to €526.5
million at constant exchange rates (+3.5%) and €533.4 million at
current exchange rates.
- The performance of MRI**, on a like-for-like
basis (period and scope), shows an increase of 3.2% to €203.4
million at constant exchange rates (€206 million at current
exchange rates).
- CT/Cath Lab** sales grew 3.9% to
€314.4 million at constant exchange rates thanks to good sales
of Optiray® (€318.4 million at current exchange rates).
- Interventional Imaging represents 9% of the
Group’s revenue as of September 30th. It shows revenue at constant
exchange rates of €51.7 million, up 11.0% (€53.3 million at current
exchange rates).
Objectives unchanged
The solid growth seen during the quarter
provides reassurance that the Group will achieve its 2019
objectives.
* At constant exchange rates:
amounts and rates of growth are calculated by cancelling out the
exchange rate effect, which is defined as the difference between
the indicator’s value for period N, converted at the exchange rate
for period N-1, and the indicator’s value for
period N-1.
** As a reminder, the MRI and
CT / Cath Lab divisions now include sales of injection systems and
related consumables.
Upcoming events:
Publication of 2019 annual revenue13
February 2020 after trading
About
Guerbet
Guerbet is a pioneer in the contrast-agent
field, with more than 90 years’ experience, and is a leader in
medical imaging worldwide. It offers a comprehensive range of
pharmaceutical products, medical devices, and services for
diagnostic and interventional imaging to improve the diagnosis and
treatment of patients. With 8% of revenue dedicated to R&D and
more than 200 employees distributed across its four centres in
France, Israel, and the United States, Guerbet is a substantial
investor in research and innovation. Guerbet (GBT) is listed on
Euronext Paris (segment B – mid caps) and generated
€790 million in revenue in 2018. For more information about
Guerbet, please visit www.guerbet.com
Forward-looking statements
Certain information contained in this press
release does not reflect historical data but constitutes
forward-looking statements. These forward-looking statements are
based on estimates, forecasts, and assumptions, including but not
limited to assumptions about the current and future strategy of the
Group and the economic environment in which the Group operates.
They involve known and unknown risks, uncertainties, and other
factors that may result in a significant difference between the
Group’s actual performance and results and those presented
explicitly or implicitly by these forward-looking statements.
These forward-looking statements are valid only
as of the date of this press release, and the Group expressly
disclaims any obligation or commitment to publish an update or
revision of the forward-looking statements contained in this press
release to reflect changes in their underlying assumptions, events,
conditions, or circumstances. The forward-looking statements
contained in this press release are for illustrative purposes only.
Forward-looking statements and information are not guarantees of
future performance and are subject to risks and uncertainties that
are difficult to predict and are generally beyond the Group’s
control. These risks and uncertainties include but are not limited
to the uncertainties inherent in research and development, future
clinical data and analyses (including after a marketing
authorisation is granted), decisions by regulatory authorities
(such as the US Food and Drug Administration or the European
Medicines Agency) regarding whether and when to approve any
application for a drug, process, or biological product filed for
any such product candidates, as well as their decisions regarding
labelling and other factors that may affect the availability or
commercial potential of such product candidates. A detailed
description of the risks and uncertainties related to the Group’s
businesses can be found in Chapter 4.4 “Risk Factors” of the
Group’s Registration Document filed with the French Financial
Markets Authority (AMF) under number D-18-0387 on 25 April
2018, available on the Group’s website (www.guerbet.com).
For more information about Guerbet, please visit
www.guerbet.com
Contacts
Jerome
EstampesChief Financial Officer+33 (0)1 45 91 50
00 |
Financial
CommunicationsBenjamin Lehari+33 (0)1 56 88 11
25blehari@actifin.fr PressJennifer Jullia+33
(0)1 56 88 11 19jjullia@actifin.fr |
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024